[Show abstract][Hide abstract] ABSTRACT: Hybridomas producing human monoclonal antibodies (MAbs) against herpes simplex virus (HSV) were established by fusing human
tonsillar lymphocytes with mouse myeloma cells. Three hybridomas have been stably producing MAbs for >16 months. All three
MAbs — H1, H2, and H3 — were of the IgGl isotype and recognized the gB glycoprotein of HSV types 1 and 2 (HSV-1 and HSV-2).
MAbs H2 and H3 not only bound to the surface membrane of HSV-infected cells but also neutralized both HSV-1 and HSV-2, whereas
MAb HI had neither activity. In mouse infection experiments, MAbs H2 and H3 showed a potent protective effect against HSV-1
infection, whereas MAB H1 was less protective. Furthermore, the development of zosteriform skin lesions in athymic nude mice
was suppressed by administering MAb H2. These results suggest that human MAbs might provide passive immunization against HSV
infections in humans.
No preview · Article · Feb 1987 · The Journal of Infectious Diseases